Revolution Medicines Drug Targets 'Undruggable' Cancer

Cover art for Revolution Medicines Drug Targets 'Undruggable' Cancer

TL;DR: Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks. Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks. Revolution Medicines earned approval for Rasonque, a medicine for pancreatic cancer targeting RAS-addicted cancers. Rasonque generated $198 million in five weeks, marking the strongest oncology drug launch on record.

Prosper Junior BakinyNov 20, 2026

From · · · 1m 10s

TL;DR: Revolution Medicines Drug Targets 'Undruggable' Cancer

Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks.

Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks. Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks. Revolution Medicines earned approval for Rasonque, a medicine for pancreatic cancer targeting RAS-addicted cancers. Rasonque generated $198 million in five weeks, marking the strongest oncology drug launch on record.

  • Rasonque Approval
  • Strong Launch
  • Clinical Results
  • RAS-Addicted Cancers

Read the story version — the same reporting as a swipeable deck of 7 cards.

Read the original on The Motley Fool

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on revolution medicines and related topics.